Nov 15 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) Inc VRX.TO , a heavily indebted Canadian drugmaker trying to sell non-core assets, has received offers for some core businesses, Chief Executive Joe Papa said on Tuesday.
Papa, speaking at a Stifel investor conference in New York, did not specify which businesses had attracted offers, but said the company would look at any substantial proposals.